Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like O*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000192 OWP Pharmaceuticals, Inc. 03/31/2022 69102013710 Lamotrigine USP Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets 02/01/2022 32.00 680.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000192 OWP Pharmaceuticals, Inc. 03/31/2022 69102030001 Subvenite (lamotrigine USP) Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets 02/01/2022 32.00 680.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None